Cerberus Therapeutics is engineering the immune system
Utilizing the small, but mighty, alpaca-derived nanobodies as versatile drug targeting agents
Initial programs focus on developing therapies for autoimmune and infectious diseases
Cerberus Therapeutics utilizes nanobodies-based platform to create novel therapeuties for modulating the immune system.
The COVID-19 pandemic highlights the need for safe and accessible therapies to engineer our immune responses. We have developed strategies that allows for precise turning on/off the immune system in response to diseases.
Our pilot programs focus on autoimmune disorders and infectious diseases based on novel biological discoveries originating from decades of work by our three founders:
Dr. Novalia Pishesha, Prof. Hidde Ploegh, and Prof. Harvey Lodish.
As a growing biotech startup, we are always looking for new team members. Whether you’re interested in the science, business development, or have something unique to bring to the team, we’d love to chat with you! We value team players who are driven by challenges and curiosity. Reach out to us and send your CV to email@example.com
Establishing and executing protocols in immunology, performing ex vivo, and in vivo assays with the goal of investigating the efficacy of Cerberus’ novel therapeutic leads as treatment for autoimmune diseases.
Working together in team with the goal of advancing Cerberus’ novel therapeutic leads as treatment for autoimmune diseases.